trichrome) and local macrophage and adipokine distributions were evaluated by immunohistochemical staining. Results To exclude acute inflammation as a consequence of the surgery, we confirmed normal levels of IL-6 in all animals. Histological scoring of the mice confirmed OA induction in DMM mice, which was increased when DMM was combined with HFD. Systemic leptin levels were significantly elevated by HFD at all timepoints, but DMM led to a decrease in leptin (3/6 groups significant, e.g. 4 weeks HFD healthy 86.9 ±17 ng/ml vs. DMM 25.8±15.6 ng/ml). Systemic levels of visfatin, adiponectin and IL-6 did not show strong reactions to diet. Noteworthy, adiponectin was systemically increased by OA induction, but only 8 weeks after surgery (e.g. HFD healthy 6148.65±637.64 ng/ml vs. HFD healthy 5175.95 ±417.74 ng/ml). Conclusions OA induced by DMM was aggravated when combined with HFD. Leptin levels in the mouse sera were elevated by HFD but reduced by DMM, which could not be observed for visfatin. Adiponectin seems to play a role in later stages of OA development, since it was solely elevated in later stages of OA. The results show that systemic levels of adipokines can be influenced by DMM and/or HFD.
Background During rheumatoid arthritis (RA), steroids and biotherapies are two different ways to diminish inflammation, by reducing cytokine production and they are used alone and combined. Their efficacy has been established in clinical trials but their differential effects at the cellular level are less documented. The aim was to study these cellular effects using an in vitro model with synoviocytes interacting with peripheral blood mononuclear cells (PBMC) to reproduce the interactions in the RA synovium. Materials and Methods Activated-PBMC were co-cultured with RA synoviocytes during 48 hour. A dose-response of methylprednisolone (MP) was tested and different biotherapies (Infliximab, Etanercept, Adalimumab, Tocilizumab, Abatacept and Rituximab) were added alone or in combination with MP. Cytokine production (IL-17, IL-6, IL-1b, IFN-g and IL-10) was measured by ELISA. Results Addition of MP to co-cultures inhibited the production of pro-inflammatory cytokines, IL17, IL-6, IL-1b and IFN-g, but also the anti-inflammatory IL-10 secretion. The lower doses of MP were mostly as efficient as higher doses. The response to the biotherapies alone was treatment-dependent and the inhibitory effect was obtained with the lower dose. IL-17 production was inhibited only by Tocilizumab (p=0.004) while IL-6 was decreased only by Infliximab (p£0.002). IL-1b level was affected in all conditions (p£0.03). IFN-g production was mainly decreased by Infliximab (p=0.004), and IL-10 by Infliximab and Tocilizumab (p£0.004). The combination MP and biotherapies, even at low doses did not induce an additional effect on the inhibition of pro-inflammatory cytokine production. Further, the addition of a biotherapy seemed to reduce the effect of MP alone. Nevertheless, the combination MP and biotherapies induced a higher IL-10 secretion than MP alone, mainly with Rituximab. Conclusion Steroids inhibited the secretion of all cytokines, and low doses were as potent. A global inhibitory effect of all biotherapies was observed but with differences between treatments depending on their mechanism of action. MP and biotherapy combination did not enhance the inhibitory effect on pro-inflammatory cytokines but could have a beneficial effect by increasing IL-10 production. Background Cytokine-mediated immunity plays a crucial role in the pathogenesis of various autoimmune diseases including systemic lupus erythematosus (SLE). The aim of this study was to evaluate association between serum levels of IL-23 and vascular involvement in SLE patients. Materials and methods Study was performed in 94 SLE patients (82 women and 12 men) aged 19-73 years and in 27 age and gender matched controls. Serum IL-23 was measured with ELISA method using R and D Systems tests.
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Carotid intima-media thickness and the presence of atherosclerotic plaques in carotid and lower extremities arteries were analysed with B-mode ultrasound. Ankle-brachial and high resistance indexes
were measured with Doppler ultrasonography.
We took into account classical cardiovascular risk factors (hypertension, dyslipidemia, hyperglycemia, overweight/obesity, smoking, oral contraceptives, positive family history of cardiovascular disease), selected clinical manifestations (cardiovascular, cerebrovascular, lupus nephritis, Raynaud's phenomenon, livedo reticularis, vasculitis, other thromboembolic complications), profile of autoantibodies (antinuclear, antiphospholipid, anti-neutrophil cytoplasmic, anti-endothelial cell).
Statistical analysis was performed with: chi 2 Yates, chi 2 Pearson, rank Spearman correlations tests, logistic regression analysis and multivariate stepwise analysis. Results Concentrations of IL-23 significantly differed between SLE patients and the controls (p=0.0005). Patients with high levels of IL-23 more frequently developed atherosclerosis showed as the presence of plaques in right common femoral artery (OR=10.1; 95% CI:1.2-85.1) and lupus nephritis (OR=3.2; 95% CI:1.1-9.6). Among classical atherosclerotic risk factors only obesity was significantly associated with IL-23 (OR=3.8; 95% CI:1.2-12.3). Immunological characteristics significantly related to IL-23 were anti-phosphatidylethanolamine antibodies (OR=12.7; 95% CI:1.5-108.1) and anti-SS-B antibodies (OR=11.8; 95% CI:1.5-94.8). Association with anticardiolipin and anti-prothrombin antibodies was on the border
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